Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. (Q53129637)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 May 2012

Language	Label	Description	Also known as
English	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.	scientific article published on 29 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

18

object named as

Jan Delabie

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Marie Nordström

9

object named as

Marie Nordström

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

2

object named as

Arne Kolstad

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

4

object named as

Mats Jerkeman

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Nils Hermann Nilsson-Ehle

14

object named as

Herman Nilsson-Ehle

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Christian Geisler

1

object named as

Christian H Geisler

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

21

object named as

Erkki Elonen

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

5

object named as

Riikka Räty

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Marja-Liisa Karjalainen-Lindsberg

19

object named as

Marja-Liisa Karjalainen-Lindsberg

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Elisabeth Ralfkiaer

15

object named as

Elisabeth Ralfkiaer

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

16

object named as

Mats Ehinger

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Nordic Lymphoma Group

22

object named as

Nordic Lymphoma Group

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Mikael Eriksson

8

object named as

Mikael Eriksson

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Grete Fossum Lauritzsen

13

object named as

Grete F Lauritzsen

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

10

object named as

Eva Kimby

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Lone Bredo Pedersen

7

object named as

Lone B Pedersen

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

author name string

Anna Laurell

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Niels S Andersen

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Hans Bentzen

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Outi Kuittinen

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Christer Sundström

17

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Peter Brown

20

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

language of work or name

0 references

publication date

29 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

158

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

355-362

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2012.09174.X

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53129637&oldid=2068353750"